Gan & Lee Pharmaceuticals. Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals.

603087

Rang in aandelen #3011
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Aandeelprijs
$10.03
Marktkapitalisatie
$5.99B
Verandering (1 dag)
-3.71%
Verandering (1 jaar)
2.30%
Land
CN
Handel Gan & Lee Pharmaceuticals. (603087)

Categorie

Healthcare
EPS voor Gan & Lee Pharmaceuticals. (603087)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Gan & Lee Pharmaceuticals. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Gan & Lee Pharmaceuticals. van 2013 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
2025 $0.28 93.61%
2024 $0.14 68.04%
2023 $0.08 -174.98%
2022 $-0.11 -127.75%
2021 $0.41 21.57%
2020 $0.34 12.22%
2019 $0.30 11.04%
2018 $0.27 -18.21%
2017 $0.33 50.25%
2016 $0.22 59.66%
2015 $0.14 39.19%
2014 $0.10 35.86%
2013 $0.07 0.00%
EPS van vergelijkbare bedrijven of concurrenten